Comparable HCT Outcomes for Patients with de novo or Secondary AML in CR1

A single-center study of 264 patients with de novo acute myeloid leukemia (AML; n=180) and secondary AML (sAML; n=84) in first complete remission (CR1) undergoing allogeneic hematopoietic cell transplantation (HCT) has shown that both patient groups have comparable long-term outcomes. Patients had a median age of 51 years (range, 18-71), and were transplanted between 1999 and 2013. At a median follow up of 6.4 years, univariate and multivariate analyses showed no significant differences between de novo AML and sAML for overall survival, leukemia-free survival, cumulative incidence of relapse, and non-relapse mortality. The authors concluded that “although sAML demonstrates outcomes inferior to de novo AML treated with chemotherapy alone, outcomes following allogeneic HCT are comparable between the two groups.”

Michelis FV, et al. Bone Marrow Transplant

Related Resources